Filing Flows › Health Care › Maze Therapeutics (MAZE)
Maze Therapeutics (MAZE) earnings and revenue breakdown
Latest: Q1 2026 · 10-Q filed May 12, 2026 · Maze Therapeutics (MAZE) Q1 2026 earnings results →
Q1 2026 121¢ of every $1 of revenue lost · operating margin -132.8%
Maze Therapeutics made $20.0M in Q1 2026. Operating margin -132.8%, net loss $24.2M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed May 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $20.0M in Q1 2026.
Operating costs exceeded revenue by $26.6M, an operating margin of -132.8%. The quarter ended with a net loss of $24.2M.
Operating cash flow was −$39.1M. Non-cash charges added back $444K of depreciation and $7.1M of share-based compensation. Working capital and other items used $22.5M. Capital expenditures of $93K exceeded it, leaving free cash flow of −$39.2M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q1 2026 | 10-Q | May 12, 2026 | $20.0M | — | -132.8% | −$24.2M | −$39.1M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Maze Therapeutics
Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass™ platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze’s pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com , or follow Maze on LinkedIn and X .
In its own words, from its 8-K, filed Aug 11, 2026.
Maze Therapeutics against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Operating margin: -132.8% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| MAZE Maze Therapeutics | Q1 2026 | $20.0M | — | -132.8% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Maze Therapeutics 10-Q on SEC EDGAR · CIK 1842295 · Biological Products, (No Diagnostic Substances)
13F: who owns MAZE and who is buying
More on MAZE
History
Every quarter: Q1 2026 results